\
&
Contact us
\
&
Contact us
Published on | 4 years ago
Programmes RI FET HealthUpdate 14/9/20: The pre-proposal submission deadline has been postponed to 30 September 2020 17:00 (Brussels time). The proposal submission deadline has been postponed to 23 October 2020 17:00 (Brussels time).
The Human Brain Project (HBP) launches four calls for expression of interest (CEoIs) for new projects to directly contribute to the development of the research Infrastructure EBRAINS and increase the scope of its application in terms of innovation, neuroscience and clinical research:
1) Brain Atlas and simulation engine adapter construction
2) Application of functional architectures supporting advanced cognitive functions to address AI problems of industrial relevance
3) High-level neuro-symbolic processing for guidance of goal-directed behavior
4) Engagement of Industry, SMEs and start-ups
The first three CEoI are open to both non-HBP and HBP partners, the fourth to only non-HBP partners. The pre-proposal submission deadline is 16 September 2020 at 17:00 (Brussels time). The proposal submission deadline is 16 October 2020 at 17:00 (Brussels time). The call documents of the four calls for expression of interest provide more information on eligibility conditions, the submission and evaluation procedure. Any questions can be directed to info@opencalls.humanbrainproject.eu.
HBP Specific Grant Agreement 3 project
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
